Morphine and endorphins modulate dopamine turnover in rat median eminence.
The is evidence that some of the actions of both endogenous and exogenous opioids (e.g., stimulation of prolactin release) are mediated by interaction with catecholaminergic systems. Morphine (1.67, 5, and 15 mg/kg of body weight, intraperitoneally) altered dopamine turnover as measured by the alpha-methyl-p-tyrosine method in the median eminence, neostriatum, and frontal cortex of male Sprague-Dawley rats. The turnover rate of dopamine was reduced in the median eminence and frontal cortex but accelerated in the neostriatum. In the frontal cortex all doses were effective in decreasing dopamine turnover; however, in the median eminence the lowest dose of morphine did not significantly alter dopamine turnover. All three doses accelerated dopamine turnover in the neostriatum. Naloxone effectively reversed the effects of morphine at all doses in all brain areas, whereas it had no effect on turnover when given alone. In the median eminence, neostriatum, and frontal cortex, intraventricular injection of [D-Ala2,D-Leu5]-enkephalin (25 micrograms) or beta-endorphin (15 micrograms) produced the same effects on dopamine turnover as morphine. The actions of these peptides were blocked by naloxone. It is hypothesized that opiates and opioid peptides increase prolactin release by reducing the activity of the tuberoinfundibular dopaminergic system.
D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D004723:Endorphins / Q000494:pharmacology*; D004745:Enkephalins / Q000494:pharmacology; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000378:metabolism*; D008781:Methyltyrosines / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology*; D051381:Rats
D004723:Endorphins; D004745:Enkephalins; D008781:Methyltyrosines; D009020:Morphine; D004298:Dopamine